Figure 2.
Everolimus Treatment Duration in (A) RECORD-1 (REnal Cell Cancer Treatment With Oral RAD001 Given Daily) and (B) REACT (RAD001 Expanded Access Clinical Trial in RCC) for the Overall Populations and for Patients With Hyperglycemia or Hypercholesterolemia.
aSafety Population (n = 274); 3 Patients Who Were Randomized Were Excluded From the Safety Population